Breaking, 2026-04-22. We will update when the CMS primary-source text on Bridge LIS cost-sharing is confirmed.
Before Massachusetts Medicaid expanded coverage of semaglutide and tirzepatide in April 2024, Black patients at a tertiary-care weight-management clinic in Boston were 49 percent less likely to be prescribed one of the two GLP-1 receptor agonists than white patients (p = 0.003). After MassHealth expanded coverage, the racial disparity diminished to non-significance (Wasden et al., Obesity 2026, PMID 41771653). A parallel 2026 analysis of a Yale Health staff-model HMO where 6,225 adults had uniform coverage terms for anti-obesity medications reported that Black race was not associated with reduced GLP-1 prescription receipt (adjusted OR 0.94, 95 percent CI 0.78 to 1.13; Chen et al., Journal of General Internal Medicine 2026, PMID 40588707).
Read together, the two studies establish the mechanism. Differential insurance coverage terms produce racial disparity in GLP-1 access. Uniform coverage terms make that disparity disappear.
The Centers for Medicare and Medicaid Services announced on 2026-04-21 that the Medicare Part D GLP-1 Bridge program will be extended through December 2027. Secondary reporting by Fierce Healthcare and analyses by the Kaiser Family Foundation describe the Bridge as setting a $50 monthly beneficiary copay for covered GLP-1 medications at participating plans, and describe the Bridge as separate from Part D Low-Income Subsidy (LIS) cost-sharing protection. The CMS primary-source text for the 2026 Bridge announcement was not reachable from multiple cms.gov paths at the time of this writing; we will update this piece when the CMS-primary text confirms copay, LIS treatment, and the participating-plan list.
The Part D coverage-gap mechanism has reproduced adherence disparities before
A 2012 Annals of Internal Medicine paper by Pengxiang Li, Jalpa Doshi, and colleagues at the University of Pennsylvania examined what happened to Medicare Part D beneficiaries when they hit the doughnut-hole coverage gap without additional gap-phase protection. Antihypertensive nonadherence was 60 percent higher in the unprotected group (adjusted OR 1.60, 95 percent CI 1.50 to 1.71; PMID 22665815). The mechanism the paper names is the one the 2026 GLP-1 papers document: when cost-sharing is non-uniform, adherence disparity follows.
If the Bridge program's $50 monthly copay applies uniformly to beneficiaries regardless of LIS status, the Part D structural pattern repeats. Black Medicare beneficiaries disproportionately enroll in LIS under existing Part D rules; that enrollment is what shields them from doughnut-hole cost-sharing. A Bridge program that bypasses LIS cost-sharing protection is non-uniform coverage by another name.
What the Bridge reportedly does
Per secondary reporting, the Bridge extension runs through December 2027 and sets the beneficiary copay at $50 per month at participating Part D plans. Plan participation for the 2027 coverage year is still being confirmed; Humana, CVS/Aetna, and UnitedHealthcare intent-to-participate inquiries are outstanding. When the CMS participating-plan list publishes, this piece will carry the specific plans and the specific copay language confirmed from the CMS source.
Black Part D LIS enrollees are the population most exposed to the Bridge
Black Americans make up a disproportionate share of Part D Low-Income Subsidy enrollees. Exact cells from CMS Medicare Current Beneficiary Survey (MCBS) and the CMS Part D LIS annual report were not reachable from cms.gov paths at publication; Kaiser Family Foundation analyses put the Black LIS enrollment share above the white share, and MedPAC's 2024 annual report treats LIS as a structural protection disproportionately reached by Black beneficiaries. The primary-source MCBS 2023 LIS race-composition cell is on this piece's update list.
The population carrying the Bridge exposure most acutely is therefore Black Medicare beneficiaries with obesity, type 2 diabetes, or cardiovascular indications for semaglutide or tirzepatide therapy.
Who is on the record
Fatima Cody Stanford, MD, MPH, MPA, MBA, is an obesity-medicine physician-scientist at the Massachusetts General Hospital Weight Center and an associate professor at Harvard Medical School. Stanford is the US clinician most closely associated with the research on Black-patient access to GLP-1 therapies and the clinical-bias literature underlying the MassHealth and Yale findings.
Jalpa Doshi, PhD, is a Senior Fellow at the University of Pennsylvania's Leonard Davis Institute of Health Economics and co-author of the 2012 Part D coverage-gap paper cited above. Doshi is the US academic most closely associated with Part D structural design and its effects on adherence.
Two questions Black Medicare beneficiaries can ask their plan before the Bridge year starts
"Is my Part D plan participating in the Bridge program for 2027, and what is the monthly copay?" The participating-plan list is CMS's to publish. Readers can ask their plan directly now and get the answer before the coverage year begins.
"Does Extra Help (LIS) cost-sharing protection apply to Bridge prescriptions?" This is the editorial hinge. If the answer is yes, the Bridge aligns with existing LIS protection and the racial-disparity mechanism does not activate. If the answer is no, beneficiaries who qualify for Extra Help can ask their pharmacy whether LIS cost-sharing will be honored directly at the point of sale regardless of the Bridge's rules.
Readers who are uncertain of their LIS status can confirm it at the Social Security Administration's Extra Help page or by calling 1-800-MEDICARE.
Update plan
We will update this piece when CMS publishes the Bridge participating-plan list for 2027, when the CMS primary-source text on Bridge LIS cost-sharing is confirmed, when the CMS MCBS 2023 Black/white LIS enrollment cell is sourced directly, and when a named Black Medicare beneficiary on the record can be reached for a clinical-access perspective.
